Identification

Name
Lamotrigine
Accession Number
DB00555  (APRD00570)
Type
Small Molecule
Groups
Approved, Investigational
Description

Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class used in the treatment of epilepsy and bipolar disorder. For epilepsy it is used to treat partial seizures, primary and secondary tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. Lamotrigine also acts as a mood stabilizer. It is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. In the US, lamotrigine is available as oral tablets under the market name Lamictal. Chemically unrelated to other anticonvulsants, lamotrigine has relatively few side-effects and does not require blood monitoring. While lamotrigine is primarily indicated for epilepsy and bipolar disorders, there is evidence that it could have some clinical efficacy in some neuropathic pain states. Lamotrigine is also used as an off-label drug in treating other neurologic and psychiatric pathologies like borderline personality disorder [6]. The exact mechanism of action of lamotrigine is not fully elucidated, as it may have multiple cellular actions that contribute to its broad clinical efficacy.

Structure
Thumb
Synonyms
  • 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
  • Lamotrigina
  • Lamotrigine
  • Lamotriginum
External IDs
BW 430 C / BW 430C / BW-430C / GW 273293
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LamictalTablet100 mg/1OralPd Rx Pharmaceuticals, Inc.1995-01-17Not applicableUs
LamictalTablet150 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-02-292017-11-07Us
LamictalTablet100 mg/1OralGlaxosmithkline Inc1995-01-17Not applicableUs00173 0642 55 nlmimage10 c518e287
LamictalTablet150 mg/1OralRebel Distributors1995-01-17Not applicableUs00173 0643 60 nlmimage10 f118f8a7
LamictalTablet2 mgOralGlaxosmithkline Inc2001-09-13Not applicableCanada
LamictalTablet100 mgOralGlaxosmithkline Inc1995-12-31Not applicableCanada
LamictalTablet100 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-02-292017-11-07Us
LamictalTablet, chewable25 mg/1OralGlaxosmithkline Inc1998-09-03Not applicableUs00173 0527 00 nlmimage10 b518daa6
LamictalTablet100 mg/1OralPhysicians Total Care, Inc.2008-05-09Not applicableUs
LamictalTablet200 mg/1OralGlaxosmithkline Inc1995-01-18Not applicableUs00173 0644 60 nlmimage10 b218d956
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-lamotrigineTablet25 mgOralApotex Corporation2002-03-18Not applicableCanada
Apo-lamotrigineTablet100 mgOralApotex Corporation2002-03-18Not applicableCanada
Apo-lamotrigineTablet150 mgOralApotex Corporation2002-03-18Not applicableCanada
Auro-lamotrigineTablet150 mgOralAuro Pharma Inc2012-06-13Not applicableCanada
Auro-lamotrigineTablet100 mgOralAuro Pharma Inc2012-06-13Not applicableCanada
Auro-lamotrigineTablet25 mgOralAuro Pharma Inc2012-06-13Not applicableCanada
Dom-lamotrigineTablet150 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-lamotrigineTablet100 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-lamotrigineTablet25 mgOralDominion PharmacalNot applicableNot applicableCanada
LamotrigineTablet200 mg/1OralAlembic Pharmaceuticals Limited2018-02-05Not applicableUs
International/Other Brands
Convulsan (Actavis) / Crisomet (Juste) / Dafex (Phoenix) / Daksol (Pharmavita) / Danoptin (Pliva) / Dezepil (Rafarm) / Elmendos (GlaxoSmithKline) / Epilepax (Ivax) / Epimil (Ivax) / Epiral (Zentiva) / Epitec (Cipla Medpro) / Epitrigine (Actavis) / Labileno (GlaxoSmithKline) / Lambipol (GlaxoSmithKline) / Lamect (PharmaSwiss) / Lameptil (Sandoz) / Lameptil S (Sandoz) / Lametec (Vitalchem) / Lamez (Intas) / Lamictal / Lamictal CD (GlaxoSmithKline) / Lamictin (GlaxoSmithKline) / Lamotrix (Glenmark) / Larig (Rowex) / Medotrigin (Medochemie) / Mogine (Douglas) / Trimolep (Psicofarma) / Trogine (Ranbaxy) / Xebarin (Dr Reddys)
Categories
UNII
U3H27498KS
CAS number
84057-84-1
Weight
Average: 256.091
Monoisotopic: 255.007850663
Chemical Formula
C9H7Cl2N5
InChI Key
PYZRQGJRPPTADH-UHFFFAOYSA-N
InChI
InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)
IUPAC Name
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
SMILES
NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1

Pharmacology

Indication

Indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures/primary generalized tonic-clonic seizures/generalized seizures of Lennox-Gastaut syndrome [Label].

Indicated for conversion to monotherapy in adults (≥16 years of age) with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED)[Label].

Indicated for the maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (≥18 years of age) treated for acute mood episodes with standard therapy [Label].

Associated Conditions
Pharmacodynamics

Lamotrigine, an antiepileptic drug (AED) of the phenyltriazine class, is chemically unrelated to existing antiepileptic drugs. Lamotrigine displays a broader therapeutic profile than earilier antiepileptic drugs with significant efficacy against absence seizures [7]. Lamotrigine is thought to exert its anticonvulsant effect by stabilizing presynaptic neuronal membranes. Lamotrigine inhibits sodium currents by selectively binding to the inactivated state of the sodium channel and subsequently suppresses the release of the excilatory amino acid, glutamate. The mechanism of action of lamotrigine in reducing anticonvulsant activity is assumed to be the same for reducing biopolar depression. Lamotrigine demonstrates effectiveness in preventing the recurrence of mania and depression [7].

Lamotrigine binds to melanin-containing tissues such as eyes and pigmented skin [Label]. The metabolite of lamotrigine formed by glucuronidation, 2-N-methyl metabolite, is reported to cause dose-dependent prolongations of the PR interval, widening of the QRS complex, and, at higher doses, complete AV conduction block. Although the metabolite is only found in trace amounts in humans, the plasma concentrations of this metabolite may be increased in conditions where the extent of glucuronidation is reduced, such as liver disease [Label].

Mechanism of action

Although chemically unrelated, lamotrigine resembles the actions of phenytoin and carbamazepine in inhibiting voltage-sensitive sodium channes thereby stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory amino acids such as glutamate and aspartate [Label]. Studies on lamotrigine show binding to sodium channels similar to local anesthetics, which could explain potential clinical benefit of lamotrigine in some neuropathic pain states [7].

Lamotrigine displays binding properties to several different receptors. It mediates a weak inhibitory effect on serotonin 5-HT3 receptor with IC50 of 18 µM [Label]. It also weakly binds to Adenosine A1/A2 receptors, α1/α2/β adrenergic receptors, dopamine D1/D2 receptors, GABA A/B receptors, histamine H1 receptors, κ-opioid receptor (KOR), mACh receptors and serotonin 5-HT2 receptors with an IC50>100 µM [Label]. Lamotrigine had weak effects at sigma opioid receptors (IC50 = 145 µM) [Label]. A study demonstrated an evidence in vivo that lamotrigine inhibits Cav2.3 (R-type) calcium currents that could also contribute to its anticonvulsant activity [6]. This inhibition of calcium currents is also observed in topiramate.

TargetActionsOrganism
AVoltage-dependent R-type calcium channel subunit alpha-1E
inhibitor
Human
USodium channel protein type 2 subunit alpha
inhibitor
Human
UAdenosine receptor A1
inhibitor
Human
UAdenosine receptor A2a
inhibitor
Human
UAlpha-1A adrenergic receptor
inhibitor
Human
UAlpha-2A adrenergic receptor
inhibitor
Human
UBeta-1 adrenergic receptor
inhibitor
Human
UD(1) dopamine receptor
inhibitor
Human
UD(2) dopamine receptor
inhibitor
Human
UGABA-A receptor (anion channel)
inhibitor
Human
UGABA-A receptor (benzodiazepine site)
inhibitor
Human
UHistamine H1 receptor
inhibitor
Human
UKappa-type opioid receptor
inhibitor
Human
UMuscarinic acetylcholine receptor
inhibitor
Human
U5-hydroxytryptamine receptor 2A
inhibitor
Human
U5-hydroxytryptamine receptor 3A
inhibitor
Human
Absorption

Lamotrigine is rapidly and completely absorbed with negligible first-pass metabolism. Its oral absolute bioavailability is 98% which is not affected by food intake. Peak plasma concentrations is reached anywhere from 1.4 to 4.8 hours following drug administration, which varies depending on the dosing regimen of lamotrigine, concomitant medications, and epileptic states [Label].

Volume of distribution

The mean apparent volume of distribution (Vd/F) of lamotrigine following oral administration ranges from 0.9 to 1.3 L/kg and is independent of dose administered [Label]. Lamotrigine accumulated in the kidney of the male rat, which is atttributable to α-2 microglobulin [Label].

Protein binding

The fraction of plasma protein is 55% in vitro. Lamotrigine is not expected to undergo clinically significant interactions with other drugs through competition for protein binding sites [Label].

Metabolism

Lamotrigine predominantly undergoes glucuronidation to form 2-N-glucuronide conjugate, which is pharmacologically inactive. Of total radioactivity detected in urine following oral administration of 240 mg lamotrigine, the components recovered consisted of unchanged lamotrigine (10%), the 2-N-glucuronide (76%), a 5-N-glucuronide (10%), a 2-N-methyl metabolite (0.14%), and other unidentified minor metabolites (4%) [Label].

Route of elimination

Following oral administration of 240 mg radiolabelled lamotrigine, about 94% of total drug and its metabolites administered is recovered in the urine and 2% is recovered in the feces [Label].

Half life

The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.

Clearance

The mean apparent plasma clearance (Cl/F) ranges from 0.18 to 1.21 mL/min/kg. The values vary depending on dosing regimen, concomitant antiepileptic medications, and disease state of the individual [Label].

Toxicity

Some fatal cases of overdose involving quantities up to 15 g have been reported. Overdose has resulted in ataxia, nystagmus, increased seizures, decreased level of consciousness, coma, and intraventricular conduction delay. While there is no known antidote for lamotrigine, hospitalization and general supportive care is recommended in case of suspected overdose. If indicated, gastric lavage and emesis may be required with appropriate precautions made to protect the airway. It is uncertain whether hemodialysis is an effective means of removing lamotrigine from the blood [Label].

Oral TDLO in man is 19 mg/kg and oral TDLO (intermittent) in woman is 2 mg/kg/30H [MSDS]. Oral LD50 in mouse and rat is 205 mg/kg and 245 mg/kg, respectively [MSDS]. In animal studies, lamotrigine was not found to be teratogenic. However it decreased fetal folate concentrations in rats, an effect known to be associated with teratogenesis in animals and humans [Label]. There is no evidence of carcinogenic or mutagenic potential for lamotrigine and effect of lamotrigine on human fertility is unknown [Label].

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(2-benzhydryloxyethyl)diethyl-methylammonium iodideThe risk or severity of adverse effects can be increased when (2-benzhydryloxyethyl)diethyl-methylammonium iodide is combined with Lamotrigine.Experimental
1,10-PhenanthrolineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3-isobutyl-1-methyl-7H-xanthineLamotrigine may increase the excretion rate of 3-isobutyl-1-methyl-7H-xanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
6-O-benzylguanineLamotrigine may increase the excretion rate of 6-O-benzylguanine which could result in a lower serum level and potentially a reduction in efficacy.Investigational
7-DeazaguanineLamotrigine may increase the excretion rate of 7-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Lamotrigine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
7,9-DimethylguanineLamotrigine may increase the excretion rate of 7,9-Dimethylguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
8-azaguanineLamotrigine may increase the excretion rate of 8-azaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
8-chlorotheophyllineLamotrigine may increase the excretion rate of 8-chlorotheophylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
9-DeazaguanineLamotrigine may increase the excretion rate of 9-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
9-MethylguanineLamotrigine may increase the excretion rate of 9-Methylguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Lamotrigine.Approved, Investigational
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Lamotrigine.Investigational
AbemaciclibThe serum concentration of Lamotrigine can be increased when it is combined with Abemaciclib.Approved, Investigational
AcefyllineLamotrigine may increase the excretion rate of Acefylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Lamotrigine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Lamotrigine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Acetylglycinamide chloral hydrate.Experimental
AclidiniumThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Aclidinium.Approved
AcyclovirLamotrigine may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Lamotrigine can be increased when it is combined with Afatinib.Approved
AgmatineThe risk or severity of adverse effects can be increased when Agmatine is combined with Lamotrigine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Agomelatine.Approved, Investigational
Ajulemic acidThe risk or severity of Tachycardia and drowsiness can be increased when Lamotrigine is combined with Ajulemic acid.Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Alaproclate.Experimental
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Lamotrigine.Investigational
AlbendazoleThe serum concentration of Lamotrigine can be increased when it is combined with Albendazole.Approved, Vet Approved
AlcuroniumLamotrigine may increase the neuromuscular blocking activities of Alcuronium.Experimental
AlectinibThe serum concentration of Lamotrigine can be increased when it is combined with Alectinib.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Lamotrigine.Approved, Illicit
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Lamotrigine.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Alimemazine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Almotriptan.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lamotrigine.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Alverine.Approved, Investigational
AlvocidibThe serum concentration of Alvocidib can be decreased when it is combined with Lamotrigine.Experimental, Investigational
AmantadineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Amantadine.Approved
AmbenoniumThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Ambenonium.Approved
AmikacinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Amineptine.Illicit, Withdrawn
AmiodaroneThe serum concentration of Lamotrigine can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Lamotrigine.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Amitriptylinoxide.Approved, Investigational
AmlodipineThe serum concentration of Lamotrigine can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Lamotrigine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Lamotrigine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Amphetamine.Approved, Illicit, Investigational
Amphotericin BLamotrigine may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Lamotrigine can be decreased when combined with Amprenavir.Approved, Investigational
AmsacrineThe serum concentration of Lamotrigine can be increased when it is combined with Amsacrine.Approved, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Aniracetam.Experimental
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Lamotrigine.Approved
AnnamycinThe serum concentration of Lamotrigine can be increased when it is combined with Annamycin.Investigational
ApalutamideThe serum concentration of Lamotrigine can be decreased when it is combined with Apalutamide.Approved, Investigational
APD791The risk or severity of adverse effects can be increased when Lamotrigine is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Apramycin.Experimental, Vet Approved
AprepitantThe serum concentration of Lamotrigine can be increased when it is combined with Aprepitant.Approved, Investigational
AprobarbitalThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Arbekacin.Approved, Investigational
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Lamotrigine.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Lamotrigine.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Lamotrigine.Investigational
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Lamotrigine.Approved
AstemizoleThe serum concentration of Lamotrigine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Lamotrigine can be decreased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Lamotrigine.Approved
AtracuriumLamotrigine may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateLamotrigine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Lamotrigine.Approved, Vet Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Lamotrigine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Azaperone.Investigational, Vet Approved
AzathioprineLamotrigine may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.Approved
AZD-3043The risk or severity of adverse effects can be increased when Lamotrigine is combined with AZD-3043.Investigational
AzelastineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe serum concentration of Lamotrigine can be increased when it is combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Lamotrigine.Approved
Bafilomycin A1The serum concentration of Lamotrigine can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Lamotrigine can be increased when it is combined with Bafilomycin B1.Experimental
BamifyllineLamotrigine may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
BarbexacloneThe serum concentration of Lamotrigine can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Barbital.Illicit
Barbituric acid derivativeThe risk or severity of adverse effects can be increased when Barbituric acid derivative is combined with Lamotrigine.Experimental, Illicit
BeclamideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Beclamide.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Bekanamycin.Experimental
BelinostatThe serum concentration of Belinostat can be decreased when it is combined with Lamotrigine.Approved, Investigational
BenactyzineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Lamotrigine.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Lamotrigine.Approved
BenziloneThe risk or severity of adverse effects can be increased when Benzilone is combined with Lamotrigine.Experimental
BenzoctamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Benzoctamine.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Benzphetamine.Approved, Illicit
BenzquinamideThe serum concentration of Lamotrigine can be increased when it is combined with Benzquinamide.Withdrawn
BenzthiazideThe serum concentration of Benzthiazide can be increased when it is combined with Lamotrigine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Lamotrigine can be increased when it is combined with Bepridil.Approved, Withdrawn
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Lamotrigine.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Lamotrigine.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BicalutamideThe serum concentration of Lamotrigine can be increased when it is combined with Bicalutamide.Approved
BictegravirThe serum concentration of Bictegravir can be decreased when it is combined with Lamotrigine.Approved, Investigational
BifemelaneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Bifeprunox.Investigational
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Lamotrigine.Approved, Investigational
BinimetinibThe serum concentration of Binimetinib can be decreased when it is combined with Lamotrigine.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Lamotrigine.Approved, Investigational
Biricodar dicitrateThe serum concentration of Lamotrigine can be increased when it is combined with Biricodar dicitrate.Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Lamotrigine.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Lamotrigine.Approved
BL-1020The risk or severity of adverse effects can be increased when Lamotrigine is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Blonanserin.Approved, Investigational
BoceprevirThe metabolism of Lamotrigine can be decreased when combined with Boceprevir.Approved, Withdrawn
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Lamotrigine.Experimental
BosentanThe serum concentration of Lamotrigine can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Botulinum Toxin Type B.Approved, Investigational
Brefeldin AThe serum concentration of Lamotrigine can be increased when it is combined with Brefeldin A.Experimental
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Lamotrigine.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lamotrigine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Lamotrigine.Approved, Investigational
BromotheophyllineLamotrigine may increase the excretion rate of Bromotheophylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
BromperidolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Lamotrigine.Investigational
BuclizineThe risk or severity of adverse effects can be increased when Buclizine is combined with Lamotrigine.Approved
BufotenineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Bufotenine.Experimental, Illicit
BufyllineLamotrigine may increase the excretion rate of Bufylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Lamotrigine.Investigational
BuprenorphineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Lamotrigine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lamotrigine.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Lamotrigine.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Butethal.Approved, Illicit
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Lamotrigine.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lamotrigine.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Butriptyline.Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Butylscopolamine is combined with Lamotrigine.Approved, Investigational, Vet Approved
CabazitaxelThe serum concentration of Lamotrigine can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cabergoline.Approved
CafedrineLamotrigine may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.Investigational
CaffeineLamotrigine may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.Approved
Calcium AcetateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Phosphate.Approved
CamazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Camazepam.Approved, Illicit
CamylofinThe risk or severity of adverse effects can be increased when Camylofin is combined with Lamotrigine.Experimental
CanagliflozinThe serum concentration of Lamotrigine can be increased when it is combined with Canagliflozin.Approved
CannabidiolThe risk or severity of Tachycardia and drowsiness can be increased when Lamotrigine is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Captodiame.Approved, Investigational
CaptoprilThe serum concentration of Lamotrigine can be increased when it is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Carbinoxamine.Approved
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Lamotrigine.Approved, Investigational
CarbromalThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Carbromal.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Lamotrigine.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Caroxazone.Withdrawn
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Lamotrigine.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Lamotrigine.Approved, Investigational, Nutraceutical, Vet Approved
CathinoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cathinone.Illicit
CefoperazoneThe serum concentration of Lamotrigine can be increased when it is combined with Cefoperazone.Approved, Investigational
CeftriaxoneThe serum concentration of Lamotrigine can be increased when it is combined with Ceftriaxone.Approved
CeritinibThe serum concentration of Lamotrigine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Lamotrigine.Approved, Withdrawn
CerlapirdineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Lamotrigine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lamotrigine.Approved, Illicit, Investigational
ChlormadinoneChlormadinone may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
ChlormezanoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroformThe serum concentration of Lamotrigine can be increased when it is combined with Chloroform.Vet Approved
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lamotrigine.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Lamotrigine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chlorphenamine.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Lamotrigine.Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Lamotrigine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Lamotrigine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Lamotrigine.Approved
CilansetronThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cilansetron.Investigational
CimetidineThe serum concentration of Lamotrigine can be increased when it is combined with Cimetidine.Approved, Investigational
CimetropiumThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cimetropium.Experimental, Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cinolazepam.Approved
CisaprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumLamotrigine may increase the neuromuscular blocking activities of Cisatracurium.Approved
CitalopramThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Citalopram.Approved
ClarithromycinThe metabolism of Lamotrigine can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Lamotrigine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clidinium.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Lamotrigine.Approved, Illicit
ClofazimineThe serum concentration of Lamotrigine can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Lamotrigine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clopenthixol.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lamotrigine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lamotrigine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe metabolism of Lamotrigine can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxazolamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cloxazolam.Approved, Investigational
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Lamotrigine.Approved
CobicistatThe metabolism of Lamotrigine can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Lamotrigine.Approved, Illicit
CodeineThe serum concentration of Codeine can be decreased when it is combined with Lamotrigine.Approved, Illicit
ColchicineThe serum concentration of Lamotrigine can be increased when it is combined with Colchicine.Approved
ColistimethateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Colistin.Approved
Concanamycin AThe serum concentration of Lamotrigine can be increased when it is combined with Concanamycin A.Experimental
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Lamotrigine.Approved, Investigational
CoumaphosThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Coumaphos.Vet Approved
CP-945598The risk or severity of Tachycardia and drowsiness can be increased when Lamotrigine is combined with CP-945598.Investigational
CrizotinibThe serum concentration of Lamotrigine can be increased when it is combined with Crizotinib.Approved
CurcuminThe metabolism of Lamotrigine can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cyclizine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cyclobarbital.Experimental
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Lamotrigine.Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Lamotrigine.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Lamotrigine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cyclosporine.Approved, Investigational, Vet Approved
CycrimineThe risk or severity of adverse effects can be increased when Cycrimine is combined with Lamotrigine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Lamotrigine.Approved
Cyproterone acetateCyproterone acetate may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
DabrafenibThe serum concentration of Lamotrigine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Lamotrigine can be increased when it is combined with Daclatasvir.Approved, Investigational
DactinomycinThe serum concentration of Lamotrigine can be increased when it is combined with Dactinomycin.Approved, Investigational
DanazolThe metabolism of Lamotrigine can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Lamotrigine.Approved, Investigational, Withdrawn
DantroleneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Lamotrigine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Lamotrigine.Approved, Investigational
DarunavirThe metabolism of Lamotrigine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Lamotrigine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Lamotrigine can be increased when it is combined with Daunorubicin.Approved
DeanolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Deanol.Experimental
DecamethoniumThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Decamethonium.Approved
DeferasiroxThe serum concentration of Lamotrigine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelafloxacinThe serum concentration of Delafloxacin can be decreased when it is combined with Lamotrigine.Approved, Investigational
DelavirdineThe metabolism of Lamotrigine can be decreased when combined with Delavirdine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Delorazepam.Approved, Illicit, Investigational
DemecariumThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Demecarium.Approved
DemeclocyclineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Demeclocycline.Approved
DemegestoneDemegestone may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Lamotrigine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desloratadine.Approved, Investigational
DesmethylsertralineThe serum concentration of Lamotrigine can be increased when it is combined with Desmethylsertraline.Experimental
DesmopressinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desmopressin.Approved
DesogestrelDesogestrel may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Lamotrigine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lamotrigine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Lamotrigine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dexmethylphenidate.Approved, Investigational
DexniguldipineThe serum concentration of Lamotrigine can be increased when it is combined with Dexniguldipine.Experimental
DextofisopamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dextofisopam.Investigational
DextromethorphanThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe serum concentration of Lamotrigine can be increased when it is combined with Dexverapamil.Experimental
DezocineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Lamotrigine.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dichloralphenazone.Approved, Illicit
DichlorvosThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Dichlorvos.Vet Approved
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Lamotrigine.Approved, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Lamotrigine.Approved
DienogestDienogest may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Diethyl ether.Experimental
DiethylstilbestrolThe serum concentration of Lamotrigine can be decreased when it is combined with Diethylstilbestrol.Approved, Investigational
DifemerineThe risk or severity of adverse effects can be increased when Difemerine is combined with Lamotrigine.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Difenoxin.Approved, Illicit
DihexyverineThe risk or severity of adverse effects can be increased when Dihexyverine is combined with Lamotrigine.Experimental
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lamotrigine.Approved, Illicit
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Lamotrigine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe metabolism of Lamotrigine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dimenhydrinate.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dimethyltryptamine.Experimental, Illicit
DimetindeneThe risk or severity of adverse effects can be increased when Dimetindene is combined with Lamotrigine.Approved, Investigational
DiphemanilThe risk or severity of adverse effects can be increased when Diphemanil is combined with Lamotrigine.Experimental
Diphemanil MethylsulfateThe risk or severity of adverse effects can be increased when Diphemanil Methylsulfate is combined with Lamotrigine.Approved, Vet Approved, Withdrawn
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lamotrigine.Approved, Investigational
DiphenidolThe risk or severity of adverse effects can be increased when Diphenidol is combined with Lamotrigine.Approved, Investigational, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lamotrigine.Approved, Illicit
DipyridamoleThe serum concentration of Lamotrigine can be increased when it is combined with Dipyridamole.Approved
DisopyramideThe risk or severity of adverse effects can be increased when Disopyramide is combined with Lamotrigine.Approved
DistigmineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Distigmine.Experimental
DixyrazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dixyrazine.Experimental
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Lamotrigine.Approved
DofequidarThe serum concentration of Lamotrigine can be increased when it is combined with Dofequidar.Experimental, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Lamotrigine.Approved, Investigational
DolasetronThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dolasetron.Approved, Investigational
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Lamotrigine.Approved
Domoic AcidThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Domoic Acid.Experimental
DonepezilThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Donepezil.Approved
DopamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Doramectin.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dotarizine.Investigational
DovitinibThe serum concentration of Lamotrigine can be increased when it is combined with Dovitinib.Investigational
DoxacuriumLamotrigine may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Lamotrigine.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Lamotrigine.Approved, Investigational
DoxofyllineLamotrigine may increase the excretion rate of Doxofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
DoxycyclineThe metabolism of Lamotrigine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Lamotrigine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Illicit
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Lamotrigine.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Vet Approved
DrospirenoneDrospirenone may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dyclonine.Approved
EchothiophateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Echothiophate.Approved
EconazoleThe serum concentration of Lamotrigine can be increased when it is combined with Econazole.Approved
EcopipamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Edivoxetine.Investigational
EdrophoniumThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Edrophonium.Approved
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Lamotrigine.Approved
ElacridarThe serum concentration of Lamotrigine can be increased when it is combined with Elacridar.Investigational
ElagolixThe serum concentration of Elagolix can be decreased when it is combined with Lamotrigine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Eletriptan.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Eltanolone.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Eltoprazine.Investigational
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Lamotrigine.Approved
EluxadolineThe risk or severity of constipation can be increased when Lamotrigine is combined with Eluxadoline.Approved, Investigational
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Lamotrigine.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Emepronium.Experimental
EmopamilThe serum concentration of Lamotrigine can be increased when it is combined with Emopamil.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Emylcamate.Experimental
EnasidenibThe serum concentration of Enasidenib can be decreased when it is combined with Lamotrigine.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Lamotrigine.Approved, Investigational
EntecavirLamotrigine may increase the excretion rate of Entecavir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
EnzalutamideThe serum concentration of Lamotrigine can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Epinastine.Approved, Investigational
EpitizideThe serum concentration of Epitizide can be increased when it is combined with Lamotrigine.Experimental
EplivanserinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Lamotrigine.Approved
ErlotinibThe serum concentration of Lamotrigine can be increased when it is combined with Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Lamotrigine can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Esmirtazapine.Investigational
EsomeprazoleThe serum concentration of Lamotrigine can be increased when it is combined with Esomeprazole.Approved, Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Lamotrigine.Approved, Illicit
Estradiol acetateThe serum concentration of Estradiol acetate can be decreased when it is combined with Lamotrigine.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be decreased when it is combined with Lamotrigine.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be decreased when it is combined with Lamotrigine.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Lamotrigine can be increased when it is combined with Estramustine.Approved, Investigational
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lamotrigine.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Etacrynic acid.Approved, Investigational
EtamiphyllineLamotrigine may increase the excretion rate of Etamiphylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Lamotrigine.Experimental
EthadioneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethadione.Experimental
EthanolLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Lamotrigine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethylmorphine.Approved, Illicit
Ethynodiol diacetateEthynodiol diacetate may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Etomidate.Approved
EtonogestrelEtonogestrel may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Etoperidone.Withdrawn
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Lamotrigine.Approved
EtorphineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Lamotrigine can be decreased when it is combined with Etravirine.Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Lamotrigine.Experimental
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Lamotrigine.Approved
FabomotizoleThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fabomotizole.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Felbamate.Approved
FelodipineThe serum concentration of Lamotrigine can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenethyllineLamotrigine may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
FenfluramineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Lamotrigine.Approved
FenpiveriniumThe risk or severity of adverse effects can be increased when Fenpiverinium is combined with Lamotrigine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lamotrigine.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Fenthion.Vet Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Lamotrigine.Experimental
FenyramidolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fenyramidol.Experimental
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Lamotrigine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fexofenadine.Approved, Investigational
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Lamotrigine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluanisone.Experimental
FluconazoleThe serum concentration of Lamotrigine can be increased when it is combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Lamotrigine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Lamotrigine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Lamotrigine.Approved, Illicit, Investigational
FlurbiprofenThe serum concentration of Flurbiprofen can be decreased when it is combined with Lamotrigine.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluticasone propionate.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Lamotrigine.Experimental
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Lamotrigine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Lamotrigine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Lamotrigine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Lamotrigine can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Frovatriptan.Approved, Investigational
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Lamotrigine.Approved, Investigational
FurafyllineLamotrigine may increase the excretion rate of Furafylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
FurazolidoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Furazolidone.Approved, Investigational, Vet Approved
FurosemideThe serum concentration of Furosemide can be decreased when it is combined with Lamotrigine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Lamotrigine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lamotrigine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Gabapentin Enacarbil.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Gaboxadol.Investigational
GalantamineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Galantamine.Approved
GallamineLamotrigine may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Gallamine Triethiodide.Approved
GallopamilThe serum concentration of Lamotrigine can be increased when it is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Lamotrigine.Approved, Illicit, Investigational
GanciclovirLamotrigine may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Gantacurium Chloride.Investigational
GavestinelThe serum concentration of Gavestinel can be decreased when it is combined with Lamotrigine.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Gedocarnil.Experimental
GefitinibThe serum concentration of Lamotrigine can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Lamotrigine.Approved
GeneticinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Geneticin.Experimental
GenisteinThe serum concentration of Lamotrigine can be increased when it is combined with Genistein.Investigational
GentamicinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Lamotrigine is combined with GENTAMICIN C1A.Experimental
GepironeThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Gepirone.Investigational
GestodeneGestodene may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
GestrinoneGestrinone may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved
Ginkgo bilobaThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Ginkgo biloba.Approved, Investigational, Nutraceutical
GlecaprevirThe serum concentration of Lamotrigine can be increased when it is combined with Glecaprevir.Approved, Investigational
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Lamotrigine.Approved, Investigational
Glucagon recombinantLamotrigine may increase the gastrointestinal motility reducing activities of Glucagon recombinant.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Glutethimide.Approved, Illicit
GlyburideThe serum concentration of Lamotrigine can be increased when it is combined with Glyburide.Approved
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Lamotrigine.Approved, Investigational
GlycopyrroniumThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Glycopyrronium.Approved, Investigational, Vet Approved
Gramicidin DThe serum concentration of Lamotrigine can be increased when it is combined with Gramicidin D.Approved
GranisetronThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Guanfacine.Approved, Investigational
GuanineLamotrigine may increase the excretion rate of Guanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
GW842166The risk or severity of Tachycardia and drowsiness can be increased when Lamotrigine is combined with GW842166.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Lamotrigine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Harmaline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Hexapropymate.Experimental
HexobarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Hexobarbital.Approved
HexocycliumThe risk or severity of adverse effects can be increased when Hexocyclium is combined with Lamotrigine.Approved
HM-30181The serum concentration of Lamotrigine can be increased when it is combined with HM-30181.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Lamotrigine.Approved
Homatropine MethylbromideThe risk or severity of adverse effects can be increased when Homatropine Methylbromide is combined with Lamotrigine.Approved
Huperzine AThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Huperzine A.Approved, Investigational
HycanthoneThe serum concentration of Lamotrigine can be increased when it is combined with Hycanthone.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Hydracarbazine.Experimental
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Lamotrigine.Approved, Vet Approved
HydrocodoneLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Lamotrigine.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lamotrigine.Approved, Illicit
HydroxychloroquineThe serum concentration of Lamotrigine can be increased when it is combined with Hydroxychloroquine.Approved
Hydroxyprogesterone caproateHydroxyprogesterone caproate may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Hygromycin B.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Lamotrigine.Approved
HypericinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Hypericin.Investigational
HypoxanthineLamotrigine may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
IbipinabantThe risk or severity of Tachycardia and drowsiness can be increased when Lamotrigine is combined with Ibipinabant.Investigational
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Lamotrigine.Approved
IdalopirdineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Idalopirdine.Investigational
IdelalisibThe metabolism of Lamotrigine can be decreased when combined with Idelalisib.Approved
IfenprodilThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Lamotrigine.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Imagabalin.Investigational
ImatinibThe serum concentration of Lamotrigine can be increased when it is combined with Imatinib.Approved
ImidafenacinThe risk or severity of adverse effects can be increased when Imidafenacin is combined with Lamotrigine.Approved, Investigational
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Lamotrigine.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Imipramine oxide.Experimental
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Lamotrigine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Lamotrigine.Approved
IndinavirThe metabolism of Lamotrigine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Indiplon.Investigational
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Lamotrigine.Approved, Investigational
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Lamotrigine.Withdrawn
IpidacrineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Ipidacrine.Experimental
IpratropiumThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ipratropium.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Iproniazid.Withdrawn
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Lamotrigine.Approved, Investigational
IsavuconazoleThe serum concentration of Lamotrigine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Lamotrigine can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Isocarboxazid.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Lamotrigine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Lamotrigine.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Lamotrigine can be decreased when combined with Isoniazid.Approved, Investigational
IsopropamideThe risk or severity of adverse effects can be increased when Isopropamide is combined with Lamotrigine.Approved, Vet Approved
IsradipineThe serum concentration of Lamotrigine can be increased when it is combined with Isradipine.Approved, Investigational
ItoprideThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Itopride.Investigational
ItraconazoleThe metabolism of Lamotrigine can be decreased when combined with Itraconazole.Approved, Investigational
IvermectinThe serum concentration of Lamotrigine can be increased when it is combined with Ivermectin.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Lamotrigine can be increased when it is combined with Ivosidenib.Approved, Investigational
KanamycinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Lamotrigine.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Lamotrigine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe serum concentration of Ketoprofen can be decreased when it is combined with Lamotrigine.Approved, Vet Approved
L-TryptophanThe risk or severity of adverse effects can be increased when Lamotrigine is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Lamotrigine.Approved
LacosamideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lacosamide.Approved
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Lamotrigine.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Lamotrigine.Approved
LanicemineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lanicemine.Investigational
LaniquidarThe serum concentration of Lamotrigine can be increased when it is combined with Laniquidar.Investigational
LansoprazoleThe serum concentration of Lamotrigine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Lamotrigine can be increased when it is combined with Lapatinib.Approved, Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lasmiditan.Investigational
LedipasvirThe serum concentration of Lamotrigine can be increased when it is combined with Ledipasvir.Approved
LetermovirThe serum concentration of Letermovir can be decreased when it is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levetiracetam.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levodopa.Approved
LevofloxacinThe serum concentration of Lamotrigine can be increased when it is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levomilnacipran.Approved, Investigational
LevonorgestrelLevonorgestrel may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lamotrigine.Approved
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Lamotrigine.Approved
LidocaineThe serum concentration of Lamotrigine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Lamotrigine.Approved
LinagliptinThe serum concentration of Lamotrigine can be increased when it is combined with Linagliptin.Approved
LincomycinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Linezolid.Approved, Investigational
LisofyllineLamotrigine may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lithium cation.Experimental
LobucavirLamotrigine may increase the excretion rate of Lobucavir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lofentanil.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Lamotrigine can be increased when used in combination with Lofexidine.Approved, Investigational
LomerizineThe serum concentration of Lamotrigine can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Lamotrigine can be increased when it is combined with Lomitapide.Approved, Investigational
LonafarnibThe serum concentration of Lamotrigine can be increased when it is combined with Lonafarnib.Investigational
LoperamideThe serum concentration of Lamotrigine can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Lamotrigine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Lamotrigine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Lamotrigine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Lamotrigine can be increased when it is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lortalamine.Experimental
LosartanThe serum concentration of Losartan can be decreased when it is combined with Lamotrigine.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Lamotrigine.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Lamotrigine.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Lamotrigine.Approved, Investigational
LuliconazoleThe serum concentration of Lamotrigine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Lamotrigine can be decreased when it is combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lumateperone.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Lamotrigine.Approved, Investigational
LusutrombopagThe serum concentration of Lamotrigine can be increased when it is combined with Lusutrombopag.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lymecycline.Approved, Investigational
LynestrenolLynestrenol may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with m-Chlorophenylpiperazine.Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Lamotrigine.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium chloride.Approved
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Lamotrigine.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Lamotrigine.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium orotate.Experimental
Magnesium oxideThe therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Lamotrigine.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Lamotrigine.Experimental
Magnesium phosphateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium phosphate.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Lamotrigine is combined with Magnesium salicylate.Approved
Magnesium silicateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Lamotrigine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium Trisilicate.Approved
MalathionThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Malathion.Approved, Investigational
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Lamotrigine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Maprotiline.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Lamotrigine.Experimental
MazindolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Mebanazine.Withdrawn
MebeverineThe risk or severity of adverse effects can be increased when Mebeverine is combined with Lamotrigine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Mebutamate.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Medifoxamine.Experimental
Medroxyprogesterone acetateMedroxyprogesterone acetate may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
MefloquineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Mefloquine.Approved, Investigational
Megestrol acetateMegestrol acetate may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Melperone.Approved, Investigational
MepenzolateThe risk or severity of adverse effects can be increased when Mepenzolate is combined with Lamotrigine.Approved
MephenesinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Mephenoxalone.Experimental
MephenytoinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Mephenytoin.Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lamotrigine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Mesoridazine.Approved, Investigational
MestranolThe serum concentration of Lamotrigine can be decreased when it is combined with Mestranol.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Metergoline.Experimental
MetforminThe serum concentration of Metformin can be increased when it is combined with Lamotrigine.Approved
MethacyclineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Lamotrigine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methamphetamine.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Lamotrigine.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Metharbital.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Lamotrigine.Approved, Vet Approved
MethohexitalThe serum concentration of Lamotrigine can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethscopolamineThe risk or severity of adverse effects can be increased when Methscopolamine is combined with Lamotrigine.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methsuximide.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Lamotrigine.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Lamotrigine.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methylene blue.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methylpentynol.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Methylphenobarbital.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Lamotrigine.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methysergide.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Lamotrigine.Approved
MetoclopramideThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetocurineLamotrigine may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideLamotrigine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Lamotrigine.Approved
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Lamotrigine.Approved
MetyrosineLamotrigine may increase the sedative activities of Metyrosine.Approved
MianserinMianserin may increase the anticholinergic activities of Lamotrigine.Approved, Investigational
MibefradilThe metabolism of Lamotrigine can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Lamotrigine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Lamotrigine.Approved, Illicit
MidomafetamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Midomafetamine.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Lamotrigine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Milnacipran.Approved, Investigational
MinaprineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Minaprine.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Lamotrigine.Approved, Vet Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
MirabegronThe risk or severity of urinary retention can be increased when Lamotrigine is combined with Mirabegron.Approved
MirtazapineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Lamotrigine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Lamotrigine can be increased when it is combined with Mitoxantrone.Approved, Investigational
MivacuriumLamotrigine may increase the neuromuscular blocking activities of Mivacurium.Approved
MK-212The risk or severity of adverse effects can be increased when Lamotrigine is combined with MK-212.Investigational
MMDAThe risk or severity of adverse effects can be increased when Lamotrigine is combined with MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Moclobemide.Approved, Investigational
ModafinilThe serum concentration of Lamotrigine can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Molindone.Approved
MonensinThe serum concentration of Lamotrigine can be increased when it is combined with Monensin.Vet Approved
MoperoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe serum concentration of Morphine can be decreased when it is combined with Lamotrigine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when Lamotrigine is combined with MRK-409.Experimental
MuraglitazarThe serum concentration of Muraglitazar can be decreased when it is combined with Lamotrigine.Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Lamotrigine.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Lamotrigine.Approved
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
NabiximolsThe risk or severity of Tachycardia and drowsiness can be increased when Lamotrigine is combined with Nabiximols.Approved, Investigational
NafcillinThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lamotrigine.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Lamotrigine.Approved, Vet Approved
NaltrexoneThe serum concentration of Naltrexone can be decreased when it is combined with Lamotrigine.Approved, Investigational, Vet Approved
NaluzotanThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Naluzotan.Investigational
NaproxenThe serum concentration of Naproxen can be decreased when it is combined with Lamotrigine.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Neamine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Nefiracetam.Investigational
NelfinavirThe serum concentration of Lamotrigine can be decreased when it is combined with Nelfinavir.Approved
NeocitrullamonThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Neosaxitoxin.Investigational
NeostigmineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NeratinibThe serum concentration of Lamotrigine can be increased when it is combined with Neratinib.Approved, Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Netilmicin.Approved, Investigational
NetupitantThe serum concentration of Lamotrigine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Lamotrigine can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Niaprazine.Experimental
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Lamotrigine.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Lamotrigine.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Nicomorphine.Experimental
NigericinThe serum concentration of Lamotrigine can be increased when it is combined with Nigericin.Experimental
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Lamotrigine.Experimental
NilotinibThe metabolism of Lamotrigine can be decreased when combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Lamotrigine can be increased when it is combined with Nimodipine.Approved, Investigational
NisoldipineThe serum concentration of Lamotrigine can be increased when it is combined with Nisoldipine.Approved
NisoxetineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Lamotrigine.Approved
NitrendipineThe serum concentration of Lamotrigine can be increased when it is combined with Nitrendipine.Approved, Investigational
NitroprussideLamotrigine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Lamotrigine.Approved, Vet Approved
Nomegestrol acetateNomegestrol acetate may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
NomifensineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Nordazepam.Approved
NorelgestrominNorelgestromin may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
NorethisteroneNorethisterone may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved
NorethynodrelNorethynodrel may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved
NorgestimateNorgestimate may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
NorgestrelNorgestrel may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved
NorgestrienoneNorgestrienone may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Lamotrigine.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Octamoxin.Withdrawn
OlaparibThe metabolism of Lamotrigine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Olopatadine.Approved
OmeprazoleThe serum concentration of Lamotrigine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Lamotrigine.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ondansetron.Approved
ONT-093The serum concentration of Lamotrigine can be increased when it is combined with ONT-093.Investigational
OpipramolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Opium.Approved, Illicit
OrlistatOrlistat can cause a decrease in the absorption of Lamotrigine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OrphenadrineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Lamotrigine can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Lamotrigine.Experimental, Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Oxaflozane.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Oxaprotiline.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lamotrigine.Approved
OxcarbazepineThe serum concentration of Lamotrigine can be decreased when it is combined with Oxcarbazepine.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Lamotrigine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Oxitriptan.Approved, Investigational, Nutraceutical
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Lamotrigine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Oxprenolol.Approved
OxtriphyllineLamotrigine may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Lamotrigine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lamotrigine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lamotrigine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Oxypertine.Experimental
OxyphencyclimineThe risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Lamotrigine.Approved
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Lamotrigine.Investigational, Withdrawn
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Lamotrigine.Approved
OxytetracyclineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Lamotrigine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Lamotrigine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Lamotrigine.Approved
PalmidrolThe risk or severity of Tachycardia and drowsiness can be increased when Lamotrigine is combined with Palmidrol.Experimental, Nutraceutical
PalonosetronThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Palonosetron.Approved, Investigational
PancuroniumLamotrigine may increase the neuromuscular blocking activities of Pancuronium.Approved
PantoprazoleThe serum concentration of Lamotrigine can be increased when it is combined with Pantoprazole.Approved
ParaldehydeLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Paramethadione.Approved
ParaoxonThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Paraoxon.Experimental
PargylineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pargyline.Approved
ParitaprevirThe serum concentration of Lamotrigine can be increased when it is combined with Paritaprevir.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Paroxetine.Approved, Investigational
PeldesineLamotrigine may increase the excretion rate of Peldesine which could result in a lower serum level and potentially a reduction in efficacy.Experimental, Investigational
PemetrexedLamotrigine may increase the excretion rate of Pemetrexed which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Penbutolol.Approved, Investigational
PenciclovirLamotrigine may increase the excretion rate of Penciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Penimepicycline.Experimental
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Lamotrigine.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lamotrigine.Approved, Vet Approved
PenthienateThe risk or severity of adverse effects can be increased when Penthienate is combined with Lamotrigine.Experimental
PentifyllineLamotrigine may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
PentobarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Lamotrigine.Approved
PentoxifyllineLamotrigine may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved
PerazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Perazine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Lamotrigine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Lamotrigine.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Phencyclidine.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pheneturide.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Lamotrigine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pheniprazine.Withdrawn
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Lamotrigine.Approved, Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Lamotrigine.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Phensuximide.Approved
PhentermineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Phentermine.Approved, Illicit
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Lamotrigine.Approved
PhysostigmineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Physostigmine.Approved, Investigational
PibrentasvirThe serum concentration of Lamotrigine can be increased when it is combined with Pibrentasvir.Approved, Investigational
PiclozotanThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Piclozotan.Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Lamotrigine.Approved
PimavanserinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Lamotrigine.Approved
PinazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pinazepam.Experimental
PindololThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pipamperone.Approved, Investigational
PipecuroniumLamotrigine may increase the neuromuscular blocking activities of Pipecuronium.Approved
PipenzolateThe risk or severity of adverse effects can be increased when Pipenzolate is combined with Lamotrigine.Experimental
PiperidolateThe risk or severity of adverse effects can be increased when Piperidolate is combined with Lamotrigine.Experimental
PipotiazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pipotiazine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Lamotrigine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pirlindole.Approved
PitolisantThe serum concentration of Lamotrigine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Lamotrigine.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Lamotrigine.Approved, Investigational
PlazomicinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Plazomicin.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Lamotrigine.Approved, Investigational
PoldineThe risk or severity of adverse effects can be increased when Poldine is combined with Lamotrigine.Experimental
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Lamotrigine.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Lamotrigine.Approved, Vet Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Polymyxin B Sulfate.Approved, Vet Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Lamotrigine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pomalidomide.Approved
PonatinibThe serum concentration of Lamotrigine can be increased when it is combined with Ponatinib.Approved, Investigational
PosaconazoleThe metabolism of Lamotrigine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Lamotrigine.Approved, Investigational
Potassium ChlorideThe risk or severity of gastrointestinal ulceration can be increased when Lamotrigine is combined with Potassium Chloride.Approved, Withdrawn
PramipexoleLamotrigine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Lamotrigine.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Lamotrigine.Approved
PrednisoneThe serum concentration of Lamotrigine can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Lamotrigine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pridinol.Experimental
PrifiniumThe risk or severity of adverse effects can be increased when Prifinium is combined with Lamotrigine.Experimental
PrimaquineThe serum concentration of Lamotrigine can be increased when it is combined with Primaquine.Approved
ProcainamideThe serum concentration of Procainamide can be increased when it is combined with Lamotrigine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lamotrigine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Lamotrigine.Approved
ProgabideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Progabide.Approved, Investigational
ProgesteroneThe serum concentration of Lamotrigine can be increased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Lamotrigine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Lamotrigine can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Lamotrigine.Approved
PropentofyllineLamotrigine may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Lamotrigine.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Lamotrigine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Propiopromazine.Vet Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Lamotrigine.Approved, Investigational
PropofolThe serum concentration of Propofol can be decreased when it is combined with Lamotrigine.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Lamotrigine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Proxibarbal.Experimental
ProxyphyllineLamotrigine may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Lamotrigine.Approved
PRX-08066The risk or severity of adverse effects can be increased when Lamotrigine is combined with PRX-08066.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pseudoephedrine.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pyrantel.Approved, Vet Approved
PyridostigmineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Pyridostigmine.Approved, Investigational
PyrithyldioneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pyrithyldione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Lamotrigine.Approved, Illicit
QuercetinThe serum concentration of Lamotrigine can be increased when it is combined with Quercetin.Experimental, Investigational
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Lamotrigine.Approved
QuinacrineThe serum concentration of Lamotrigine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Lamotrigine.Approved
QuingestanolQuingestanol may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Lamotrigine.Approved, Investigational
QuinineThe metabolism of Lamotrigine can be increased when combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Quinupramine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Raclopride.Investigational
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Lamotrigine.Approved, Investigational
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Lamotrigine.Approved
RamelteonThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of constipation can be increased when Lamotrigine is combined with Ramosetron.Approved, Investigational
RanitidineThe serum concentration of Lamotrigine can be increased when it is combined with Ranitidine.Approved
RapacuroniumLamotrigine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Rasagiline.Approved
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Lamotrigine.Investigational
ReboxetineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Lamotrigine can be increased when it is combined with Regorafenib.Approved
RemacemideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Remacemide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lamotrigine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Lamotrigine.Approved, Investigational
RevefenacinThe risk or severity of adverse effects can be increased when Revefenacin is combined with Lamotrigine.Investigational
Reversin 121The serum concentration of Lamotrigine can be increased when it is combined with Reversin 121.Experimental
RibostamycinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ribostamycin.Approved, Investigational
RifampicinThe metabolism of Lamotrigine can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Lamotrigine can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Lamotrigine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Lamotrigine can be increased when combined with Rifaximin.Approved, Investigational
RilpivirineThe serum concentration of Lamotrigine can be increased when it is combined with Rilpivirine.Approved
RiluzoleThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Riluzole.Approved, Investigational
RimexoloneThe metabolism of Lamotrigine can be increased when combined with Rimexolone.Approved
RimonabantThe risk or severity of Tachycardia and drowsiness can be increased when Lamotrigine is combined with Rimonabant.Approved, Investigational
RisperidoneThe risk or severity of hypotension can be increased when Risperidone is combined with Lamotrigine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ritanserin.Investigational
RivastigmineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Rivastigmine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Rizatriptan.Approved
RociverineThe risk or severity of adverse effects can be increased when Rociverine is combined with Lamotrigine.Experimental
RocuroniumLamotrigine may increase the neuromuscular blocking activities of Rocuronium.Approved
RolapitantThe serum concentration of Lamotrigine can be increased when it is combined with Rolapitant.Approved, Investigational
RolipramThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Rolitetracycline.Approved
RomifidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Romifidine.Vet Approved
RopiniroleLamotrigine may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineLamotrigine may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when Lamotrigine is combined with RP-5063.Investigational
RucaparibThe serum concentration of Lamotrigine can be increased when it is combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Lamotrigine.Approved
SafinamideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Safrazine.Withdrawn
SalinomycinThe serum concentration of Lamotrigine can be increased when it is combined with Salinomycin.Vet Approved
SaquinavirThe metabolism of Lamotrigine can be decreased when combined with Saquinavir.Approved, Investigational
SaredutantThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Saredutant.Investigational
SarilumabThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Sarpogrelate.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Scopolamine.Approved, Investigational
SecobarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Secobarbital.Approved, Vet Approved
Secretin humanThe therapeutic efficacy of Secretin human can be decreased when used in combination with Lamotrigine.Approved
Secretin porcineThe therapeutic efficacy of Secretin porcine can be decreased when used in combination with Lamotrigine.Approved
SelegilineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Selegiline.Approved, Investigational, Vet Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Lamotrigine.Approved
SerotoninThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Serotonin.Investigational, Nutraceutical
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Lamotrigine.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lamotrigine.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Lamotrigine.Approved
SiltuximabThe serum concentration of Lamotrigine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Lamotrigine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Lamotrigine.Approved
SisomicinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Sisomicin.Investigational
SLV319The risk or severity of Tachycardia and drowsiness can be increased when Lamotrigine is combined with SLV319.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Lamotrigine.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Lamotrigine.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Lamotrigine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Lamotrigine.Approved
SorafenibThe serum concentration of Lamotrigine can be increased when it is combined with Sorafenib.Approved, Investigational
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Lamotrigine.Approved
St. John's WortThe serum concentration of Lamotrigine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StaurosporineThe serum concentration of Lamotrigine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Lamotrigine can be increased when it is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lamotrigine.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Lamotrigine.Approved
SulpirideLamotrigine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Sulthiame.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Lamotrigine can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenThe serum concentration of Suprofen can be decreased when it is combined with Lamotrigine.Approved, Withdrawn
SurinabantThe risk or severity of Tachycardia and drowsiness can be increased when Lamotrigine is combined with Surinabant.Investigational
SuvorexantLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TacrineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TacrolimusThe serum concentration of Lamotrigine can be increased when it is combined with Tacrolimus.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Talbutal.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Talopram.Experimental
TamoxifenThe serum concentration of Lamotrigine can be increased when it is combined with Tamoxifen.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Lamotrigine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved
TariquidarThe serum concentration of Lamotrigine can be increased when it is combined with Tariquidar.Investigational
TasimelteonThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Lamotrigine is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tedizolid phosphate.Approved
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Lamotrigine.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Lamotrigine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Lamotrigine can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Lamotrigine can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Lamotrigine.Approved, Investigational
TemsirolimusThe serum concentration of Lamotrigine can be increased when it is combined with Temsirolimus.Approved
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Lamotrigine.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Lamotrigine.Approved
TerfenadineThe serum concentration of Lamotrigine can be increased when it is combined with Terfenadine.Approved, Withdrawn
TesmilifeneThe serum concentration of Lamotrigine can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Lamotrigine can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Lamotrigine can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Lamotrigine can be increased when it is combined with Testosterone enanthate.Approved
Testosterone propionateThe serum concentration of Lamotrigine can be decreased when it is combined with Testosterone propionate.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe serum concentration of Lamotrigine can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tetrahydropalmatine.Investigational
TetrandrineThe serum concentration of Lamotrigine can be increased when it is combined with Tetrandrine.Experimental
TetrazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tetrodotoxin.Investigational
ThalidomideLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineLamotrigine may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
TheodrenalineLamotrigine may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
ThiamylalThe serum concentration of Lamotrigine can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe serum concentration of Lamotrigine can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Lamotrigine.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Lamotrigine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lamotrigine.Approved
ThonzylamineThe risk or severity of adverse effects can be increased when Thonzylamine is combined with Lamotrigine.Approved
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Lamotrigine.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tiapride.Approved, Investigational
TicagrelorThe serum concentration of Lamotrigine can be increased when it is combined with Ticagrelor.Approved
Tiemonium iodideThe risk or severity of adverse effects can be increased when Tiemonium iodide is combined with Lamotrigine.Experimental
TigecyclineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tilidine.Experimental
TimepidiumThe risk or severity of adverse effects can be increased when Timepidium is combined with Lamotrigine.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Lamotrigine.Approved
TiotropiumThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tiotropium.Approved
TipifarnibThe serum concentration of Lamotrigine can be increased when it is combined with Tipifarnib.Investigational
TipranavirThe serum concentration of Lamotrigine can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tizanidine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Lamotrigine can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tofisopam.Approved
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Lamotrigine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Lamotrigine.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tolperisone.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Lamotrigine.Approved, Investigational
TolvaptanThe serum concentration of Lamotrigine can be increased when it is combined with Tolvaptan.Approved
TopiramateThe risk or severity of hyperthermia and oligohydrosis can be increased when Lamotrigine is combined with Topiramate.Approved
ToremifeneThe serum concentration of Lamotrigine can be increased when it is combined with Toremifene.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Lamotrigine.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Lamotrigine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tricaine methanesulfonate.Vet Approved
TrichlorfonThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Lamotrigine.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Triclofos.Withdrawn
TridihexethylThe risk or severity of adverse effects can be increased when Tridihexethyl is combined with Lamotrigine.Withdrawn
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Lamotrigine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Lamotrigine.Approved
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Lamotrigine.Experimental
TrimebutineThe risk or severity of adverse effects can be increased when Trimebutine is combined with Lamotrigine.Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Trimethadione.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Lamotrigine.Approved, Investigational
TrimethoprimThe serum concentration of Lamotrigine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Lamotrigine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Lamotrigine.Approved
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Lamotrigine.Investigational, Withdrawn
TroleandomycinThe metabolism of Lamotrigine can be decreased when combined with Troleandomycin.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Lamotrigine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Lamotrigine.Approved, Investigational
TropisetronThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tropisetron.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Lamotrigine.Approved
TubocurarineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Tubocurarine.Approved
TyrothricinThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Tyrothricin.Approved
UmeclidiniumThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Umeclidinium.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Lamotrigine.Investigational
Uric AcidLamotrigine may increase the excretion rate of Uric Acid which could result in a lower serum level and potentially a reduction in efficacy.Experimental, Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Vabicaserin.Investigational
ValaciclovirLamotrigine may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ValerianThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Valerian.Approved, Experimental, Investigational
ValganciclovirLamotrigine may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ValinomycinThe serum concentration of Lamotrigine can be increased when it is combined with Valinomycin.Experimental
ValnoctamideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Valnoctamide.Investigational
ValomaciclovirLamotrigine may increase the excretion rate of Valomaciclovir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
Valproic AcidValproic Acid may decrease the excretion rate of Lamotrigine which could result in a higher serum level.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Valpromide.Experimental
ValspodarThe serum concentration of Lamotrigine can be increased when it is combined with Valspodar.Investigational
VancomycinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Vancomycin.Approved
VecuroniumLamotrigine may increase the neuromuscular blocking activities of Vecuronium.Approved
VelpatasvirThe serum concentration of Lamotrigine can be increased when it is combined with Velpatasvir.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lamotrigine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Veralipride.Experimental
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Lamotrigine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Vilazodone.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Vinbarbital.Experimental
VinblastineThe serum concentration of Lamotrigine can be increased when it is combined with Vinblastine.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Vinylbital.Experimental
VoacamineThe serum concentration of Lamotrigine can be increased when it is combined with Voacamine.Approved, Investigational
VorapaxarThe serum concentration of Lamotrigine can be increased when it is combined with Vorapaxar.Approved
VoriconazoleThe metabolism of Lamotrigine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Vortioxetine.Approved, Investigational
VoxilaprevirThe serum concentration of Lamotrigine can be increased when it is combined with Voxilaprevir.Approved, Investigational
WIN 55212-2The risk or severity of Tachycardia and drowsiness can be increased when Lamotrigine is combined with WIN 55212-2.Experimental
WortmanninThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Wortmannin.Experimental
XanthineLamotrigine may increase the excretion rate of Xanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
XP19986The risk or severity of adverse effects can be increased when Lamotrigine is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Xylazine.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Lamotrigine is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lamotrigine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Lamotrigine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Lamotrigine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Zolmitriptan.Approved, Investigational
ZolpidemLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe serum concentration of Lamotrigine can be increased when it is combined with Zomepirac.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Lamotrigine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Lamotrigine.Approved
ZosuquidarThe serum concentration of Lamotrigine can be increased when it is combined with Zosuquidar.Investigational
ZotepineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Lamotrigine.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Grahame Roy Lee, "Process for the preparation of lamotrigine." U.S. Patent US5925755, issued January, 1981.

US5925755
General References
  1. Backonja M: Neuromodulating drugs for the symptomatic treatment of neuropathic pain. Curr Pain Headache Rep. 2004 Jun;8(3):212-6. [PubMed:15115640]
  2. Barbosa L, Berk M, Vorster M: A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003 Apr;64(4):403-7. [PubMed:12716240]
  3. Jensen TS: Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain. 2002;6 Suppl A:61-8. [PubMed:11888243]
  4. Pappagallo M: Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther. 2003 Oct;25(10):2506-38. [PubMed:14667954]
  5. Tehrani SP, Daryaafzoon M, Bakhtiarian A, Ejtemaeemehr S, Sahraei H: The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9. [PubMed:19579915]
  6. Dibue-Adjei M, Kamp MA, Alpdogan S, Tevoufouet EE, Neiss WF, Hescheler J, Schneider T: Cav2.3 (R-Type) Calcium Channels are Critical for Mediating Anticonvulsive and Neuroprotective Properties of Lamotrigine In Vivo. Cell Physiol Biochem. 2017;44(3):935-947. doi: 10.1159/000485361. Epub 2017 Nov 24. [PubMed:29176325]
  7. 44. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 544, 549). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
External Links
Human Metabolome Database
HMDB0014695
KEGG Drug
D00354
PubChem Compound
3878
PubChem Substance
46505408
ChemSpider
3741
BindingDB
50031299
ChEBI
6367
ChEMBL
CHEMBL741
Therapeutic Targets Database
DAP000039
PharmGKB
PA450164
IUPHAR
2622
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Lamotrigine
ATC Codes
N03AX09 — Lamotrigine
AHFS Codes
  • 28:12.92 — Miscellaneous Anticonvulsants
FDA label
Download (1.12 MB)
MSDS
Download (24.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingBasic SciencePsychiatric Disorder NOS1
1CompletedNot AvailableHealthy Volunteers8
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentBipolar Affective Disorders / Bipolar Disorder (BD)1
1CompletedTreatmentBipolar Disorder (BD)1
1CompletedTreatmentBipolar Disorder (BD) / Epilepsies1
1CompletedTreatmentEpilepsies6
1CompletedTreatmentEpilepsies / Seizure, Absence1
1CompletedTreatmentFasting State1
1CompletedTreatmentFed1
1CompletedTreatmentHealthy Volunteers8
1CompletedTreatmentHealthy Volunteers / Psychiatric Disorder NOS2
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1TerminatedTreatmentBipolar Disorder (BD) / Healthy Volunteers1
1, 2CompletedDiagnosticBipolar Disorder (BD) / Depression, Bipolar / Epilepsies / Seizures1
1, 2RecruitingTreatmentBrain Injury1
2CompletedTreatmentAnxiety Disorders / Moods Disorders / Psychotic Disorder NOS1
2CompletedTreatmentBipolar Disorder (BD)1
2CompletedTreatmentBipolar II Disorder, Most Recent Episode Major Depressive1
2CompletedTreatmentCocaine-Related Disorders1
2CompletedTreatmentDermatillomania / Neurotic Excoriation / Pathologic Skin Picking / Psychogenic Excoriation1
2CompletedTreatmentEpilepsies2
2CompletedTreatmentMixed Mania Bipolar Disorder1
2CompletedTreatmentNeurotic Disorders / Obsessive-Compulsive Disorder (OCD)1
2CompletedTreatmentSecondary Progressive Multiple Sclerosis (SPMS)1
2RecruitingTreatmentImpaired Cognition / Impaired Synaptic Plasticity / Noonan Syndrome, Neurofibromatosis Type 11
2TerminatedTreatmentBipolar 1 Disorder1
2Unknown StatusTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
2WithdrawnTreatmentOpioid-Related Disorders1
2, 3CompletedTreatmentAddictions1
2, 3CompletedTreatmentTrigeminal Neuralgia (TN)1
2, 3RecruitingTreatmentNeurofibromatosis Type 11
3Active Not RecruitingTreatmentAdverse Effects / Epilepsy, Localization Related1
3CompletedNot AvailableSeizures1
3CompletedDiagnosticBipolar Disorder (BD)1
3CompletedSupportive CareNeurotoxicity / Pain / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentBinge Eating Disorder (BED) / BMI >30 kg/m21
3CompletedTreatmentBipolar Disorder (BD)7
3CompletedTreatmentBipolar Disorder (BD) / Depression, Bipolar2
3CompletedTreatmentChildhood Absence Epilepsy / Epilepsies / Petit Mal Epilepsy / Seizures1
3CompletedTreatmentDepression1
3CompletedTreatmentDepression, Bipolar1
3CompletedTreatmentDystrophia Myotonica Type 1 / Myotonia Congenita / Paralysis, Hyperkalemic Periodic / Paramyotonia Congenita / Potassium-Aggravated Myotonia1
3CompletedTreatmentEpilepsies6
3CompletedTreatmentEpilepsy, Localization Related2
3CompletedTreatmentMenière's Disease / Ménière's Vertigo / Vertigo, Aural / Vertigo, Intermittent1
3CompletedTreatmentMoods Disorders1
3CompletedTreatmentSchizophrenic Disorders2
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentBipolar Disorder (BD)1
3TerminatedTreatmentEpilepsies1
3WithdrawnTreatmentAlcohol Dependence / Post Traumatic Stress Disorder (PTSD)1
4Active Not RecruitingTreatmentBipolar Disorder (BD) / Depression / Depression, Bipolar / Lamotrigine / Melancholic Depression1
4Active Not RecruitingTreatmentEpilepsies1
4CompletedNot AvailableHippocampal Atrophy Due to Corticosteroid / Hypomania Due to Corticosteroid Use / Memory Impairment Due to Corticosteroid Use1
4CompletedBasic ScienceEpilepsies1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedHealth Services ResearchMemory Disturbances1
4CompletedPreventionBipolar Disorder (BD)1
4CompletedTreatmentBipolar Disorder (BD)8
4CompletedTreatmentBipolar Disorder (BD) / Dependence, Cocaine1
4CompletedTreatmentBipolar Disorder (BD) / Depression1
4CompletedTreatmentBipolar Disorder (BD) / Mania1
4CompletedTreatmentBipolar I Disorder / Bipolar II Disorder1
4CompletedTreatmentBorderline Personality Disorder (BPD)1
4CompletedTreatmentBronchial Asthma1
4CompletedTreatmentEpilepsies5
4CompletedTreatmentEpilepsy, Localization Related2
4CompletedTreatmentEpilepsy, Tonic-Clonic1
4CompletedTreatmentMajor Depressive Disorder (MDD)1
4Not Yet RecruitingBasic ScienceBariatric Surgery Candidate1
4Not Yet RecruitingBasic ScienceEpilepsies1
4RecruitingNot AvailableEpilepsies1
4RecruitingTreatmentEpilepsies1
4TerminatedTreatmentMajor Depressive Disorder (MDD)1
4Unknown StatusTreatmentAlcohol Dependence / Bipolar Disorder (BD) / Depression / Mania / Psychosis1
4Unknown StatusTreatmentEpilepsies1
Not AvailableAvailableNot AvailableAcute and Chronic Pain Following Modified Radical Mastectomy1
Not AvailableCompletedNot AvailableBipolar Disorder (BD)3
Not AvailableCompletedNot AvailableEpilepsies4
Not AvailableCompletedBasic ScienceDepression, Bipolar1
Not AvailableCompletedPreventionBipolar Disorder (BD) / Depression / Psychotic Disorder NOS / Schizophrenic Disorders1
Not AvailableCompletedTreatmentBipolar Disorder (BD)1
Not AvailableCompletedTreatmentEpilepsies1
Not AvailableCompletedTreatmentFacial Neuropathy1
Not AvailableCompletedTreatmentTrigeminal Neuralgia (TN)1
Not AvailableCompletedTreatmentUnipolar Depression1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableDepression / Suicidal Ideation1
Not AvailableRecruitingNot AvailableEpilepsies1
Not AvailableRecruitingNot AvailableObesity, Morbid1
Not AvailableRecruitingBasic ScienceBipolar Disorder (BD) / Depression, Bipolar / Unipolar Depression1
Not AvailableTerminatedTreatmentAdolescent Depression1
Not AvailableUnknown StatusTreatmentAdults With Tonic Clonic Seizures and/or Partial Seizures1

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Aurobindo pharma ltd
  • Dr reddys laboratories ltd
  • Glenmark generics ltd
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Taro pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • Smithkline beecham corp
  • Smithkline beecham corp dba glaxosmithkline
  • Apotex inc
  • Cadista pharmaceuticals inc
  • Lupin ltd
  • Matrix laboratories ltd
  • Roxane laboratories inc
  • Torrent pharmaceuticals ltd
  • Upsher smith laboratories inc
  • Wockhardt ltd
Packagers
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • Atlantic Biologicals Corporation
  • Aurobindo Pharma Ltd.
  • Cadila Healthcare Ltd.
  • Cadista Pharmaceuticals Inc.
  • Cardinal Health
  • Caremark LLC
  • Cobalt Pharmaceuticals Inc.
  • Compass Pharma Services LLC
  • Comprehensive Consultant Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • DSM Corp.
  • GlaxoSmithKline Inc.
  • Glenmark Generics Ltd.
  • Greenstone LLC
  • Heartland Repack Services LLC
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Mckesson Corp.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pharmacy Service Center
  • Physicians Total Care Inc.
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sandoz
  • Stat Rx Usa
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals
  • UDL Laboratories
  • Vangard Labs Inc.
  • Zydus Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral150 mg/1
TabletOral150 mg
TabletOral2 mg
TabletOral25 mg
TabletOral5 mg
Tablet, chewableOral2 mg/1
TabletOral200 mg
Tablet, orally disintegratingOral100 mg/1
Tablet, orally disintegratingOral200 mg/1
Tablet, orally disintegratingOral25 mg/1
Tablet, orally disintegratingOral50 mg/1
Tablet, film coated, extended releaseOral100 mg/1
Tablet, film coated, extended releaseOral200 mg/1
Tablet, film coated, extended releaseOral25 mg/1
Tablet, film coated, extended releaseOral250 mg/1
Tablet, film coated, extended releaseOral300 mg/1
Tablet, film coated, extended releaseOral50 mg/1
Kit
TabletOral100 mg/1
TabletOral200 mg/1
TabletOral25 mg/1
TabletOral250 mg/1
TabletOral50 mg/1
Tablet, chewableOral25 mg/1
Tablet, chewableOral5 mg/1
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral200 mg/1
Tablet, extended releaseOral25 mg/1
Tablet, extended releaseOral300 mg/1
Tablet, extended releaseOral50 mg/1
Tablet, for suspensionOral25 mg/1
Tablet, for suspensionOral5 mg/1
TabletOral300 mg/1
Prices
Unit descriptionCostUnit
LaMICtal Starter 98 25 (84)-100(14)mg Kit Box556.69USD box
LaMICtal XR 200 mg 24 Hour tablet12.11USD tablet
Lamictal xr 200 mg tablet11.65USD tablet
LaMICtal XR 100 mg 24 Hour tablet11.36USD tablet
Lamictal xr 100 mg tablet10.92USD tablet
Lamictal xr 50 mg tablet10.2USD tablet
Lamictal 200 mg tablet7.44USD tablet
Lamictal odt start kt (orange)7.28USD tablet
Lamictal xr start kit (orange)7.28USD tablet
Lamictal odt 200 mg tablet6.95USD tablet
Lamictal odt 100 mg tablet5.82USD tablet
Lamotrigine 200 mg tablet5.78USD tablet
LaMICtal 25 mg Chew Tabs5.63USD tab
Lamictal odt 50 mg tablet5.46USD tablet
Lamictal tab start kit (green)5.46USD tablet
Lamictal 150 mg tablet5.38USD tablet
Lamictal odt 25 mg tablet5.1USD tablet
Lamictal xr 25 mg tablet5.1USD tablet
Lamictal 100 mg tablet4.72USD tablet
Lamotrigine tablet starter kit4.24USD tablet
Lamotrigine 150 mg tablet3.98USD tablet
Lamictal 25 mg tablet3.78USD tablet
Lamotrigine 100 mg tablet3.52USD tablet
LamoTRIgine 25 mg Chew Tabs3.33USD tab
LamoTRIgine 5 mg Chew Tabs3.18USD tab
Lamotrigine 25 mg tablet2.9USD tablet
Apo-Lamotrigine 150 mg Tablet1.31USD tablet
Mylan-Lamotrigine 150 mg Tablet1.31USD tablet
Novo-Lamotrigine 150 mg Tablet1.31USD tablet
Pms-Lamotrigine 150 mg Tablet1.31USD tablet
Ratio-Lamotrigine 150 mg Tablet1.31USD tablet
Apo-Lamotrigine 100 mg Tablet0.88USD tablet
Mylan-Lamotrigine 100 mg Tablet0.88USD tablet
Novo-Lamotrigine 100 mg Tablet0.88USD tablet
Pms-Lamotrigine 100 mg Tablet0.88USD tablet
Ratio-Lamotrigine 100 mg Tablet0.88USD tablet
Apo-Lamotrigine 25 mg Tablet0.22USD tablet
Mylan-Lamotrigine 25 mg Tablet0.22USD tablet
Novo-Lamotrigine 25 mg Tablet0.22USD tablet
Pms-Lamotrigine 25 mg Tablet0.22USD tablet
Ratio-Lamotrigine 25 mg Tablet0.22USD tablet
Lamictal 5 mg Chewable Tablet0.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5698226No1995-07-292012-07-29Us
CA2277722No2001-03-272012-01-29Canada
US9144547No2003-09-222023-09-22Us
US8637512No2008-06-142028-06-14Us
US8840925No2008-07-022028-07-02Us
US7919115No2009-01-042029-01-04Us
US9339504No2008-07-022028-07-02Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)216-218 °C (uncorr)Not Available
logP2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.488 mg/mLALOGPS
logP1.87ALOGPS
logP1.93ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)14.98ChemAxon
pKa (Strongest Basic)5.87ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area90.71 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity66.62 m3·mol-1ChemAxon
Polarizability23.1 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9382
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.7155
P-glycoprotein inhibitor INon-inhibitor0.911
P-glycoprotein inhibitor IINon-inhibitor0.9604
Renal organic cation transporterNon-inhibitor0.8176
CYP450 2C9 substrateNon-substrate0.9162
CYP450 2D6 substrateNon-substrate0.9055
CYP450 3A4 substrateNon-substrate0.6862
CYP450 1A2 substrateNon-inhibitor0.611
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.7007
CYP450 2C19 inhibitorNon-inhibitor0.8594
CYP450 3A4 inhibitorNon-inhibitor0.7678
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5515
Ames testNon AMES toxic0.8202
CarcinogenicityNon-carcinogens0.7895
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7556 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9168
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0090000000-0ca7be847ef73a25032b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0c09-0890000000-f7244245bf6816d03dc7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-97d10d3ad5d45edcaeba
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-b2dbf89c13423bc1b59f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-d26cb5886894916aa1d8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0590000000-528845465e0a140f6b60
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0930000000-9a68c83a3573a48cf6c2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0kmi-0900000000-bb97e1aecda1747cbf29
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-97d10d3ad5d45edcaeba
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-97d10d3ad5d45edcaeba
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-1e756e80b9a7d4b0dd18
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0490000000-a29a09ef58e19c7e62e1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0940000000-85279d67921a0106c4e2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0kmi-0900000000-eba38744d927d1c39a74
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ab9-0790000000-036c53ed1835e3d33348
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0290000000-26664a56093e292ec551
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0190000000-33187897c9fb0b0a178f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-2940000000-1a4f3a098b426ac4febb

Taxonomy

Description
This compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Dichlorobenzenes
Alternative Parents
Aminotriazines / Imidolactams / Aryl chlorides / 1,2,4-triazines / Heteroaromatic compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
1,2-dichlorobenzene / Aminotriazine / Aryl chloride / Aryl halide / Triazine / Imidolactam / 1,2,4-triazine / Heteroaromatic compound / Organoheterocyclic compound / Azacycle
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
dichlorobenzene, primary arylamine, 1,2,4-triazines (CHEBI:6367)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1E gives rise to R-type calcium currents. R-type calcium channels belong to the 'high-voltage activated' (HVA) group and are blocked by nickel, and partially by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to dihydropyridines (DHP), omega-conotoxin-GVIA (omega-CTx-GVIA), and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing alpha-1E subunit could be involved in the modulation of firing patterns of neurons which is important for information processing.
Specific Function
Calcium channel activity
Gene Name
CACNA1E
Uniprot ID
Q15878
Uniprot Name
Voltage-dependent R-type calcium channel subunit alpha-1E
Molecular Weight
261729.05 Da
References
  1. Dibue-Adjei M, Kamp MA, Alpdogan S, Tevoufouet EE, Neiss WF, Hescheler J, Schneider T: Cav2.3 (R-Type) Calcium Channels are Critical for Mediating Anticonvulsive and Neuroprotective Properties of Lamotrigine In Vivo. Cell Physiol Biochem. 2017;44(3):935-947. doi: 10.1159/000485361. Epub 2017 Nov 24. [PubMed:29176325]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN2A
Uniprot ID
Q99250
Uniprot Name
Sodium channel protein type 2 subunit alpha
Molecular Weight
227972.64 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Lipkind GM, Fozzard HA: Molecular modeling of local anesthetic drug binding by voltage-gated sodium channels. Mol Pharmacol. 2005 Dec;68(6):1611-22. Epub 2005 Sep 20. [PubMed:16174788]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
IC50>100 µM
General Function
Purine nucleoside binding
Specific Function
Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
ADORA1
Uniprot ID
P30542
Uniprot Name
Adenosine receptor A1
Molecular Weight
36511.325 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
IC50>100 µM
General Function
Identical protein binding
Specific Function
Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
Gene Name
ADORA2A
Uniprot ID
P29274
Uniprot Name
Adenosine receptor A2a
Molecular Weight
44706.925 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
IC50>100 µM
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
IC50>100 µM
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
IC50>100 µM
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
IC50>100 µM
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.

Components:
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
IC50>100 µM
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
IC50>100 µM
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...

Components:
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
IC50>100 µM
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
IC50>100 µM
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
IC50>100 µM
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...

Components:
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
IC50>100 µM
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
IC50 = 18 µM
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein homodimerization activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A4
Uniprot ID
P22310
Uniprot Name
UDP-glucuronosyltransferase 1-4
Molecular Weight
60024.535 Da
References
  1. Argikar UA, Senekeo-Effenberger K, Larson EE, Tukey RH, Remmel RP: Studies on induction of lamotrigine metabolism in transgenic UGT1 mice. Xenobiotica. 2009 Nov;39(11):826-35. doi: 10.3109/00498250903188985. [PubMed:19845433]
  2. Chen H, Yang K, Choi S, Fischer JH, Jeong H: Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. Drug Metab Dispos. 2009 Sep;37(9):1841-7. doi: 10.1124/dmd.109.026609. Epub 2009 Jun 22. [PubMed:19546240]
  3. Argikar UA, Remmel RP: Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 2009 May;39(5):355-63. doi: 10.1080/00498250902745082. [PubMed:19387891]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Nadph binding
Specific Function
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA pre...
Gene Name
DHFR
Uniprot ID
P00374
Uniprot Name
Dihydrofolate reductase
Molecular Weight
21452.61 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
References
  1. Argikar UA, Remmel RP: Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 2009 May;39(5):355-63. doi: 10.1080/00498250902745082. [PubMed:19387891]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inducer
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. doi: 10.1124/dmd.104.000794. Epub 2004 Aug 10. [PubMed:15304429]
  2. Interactions [Link]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. [PubMed:22039822]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Luna-Tortos C, Fedrowitz M, Loscher W: Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008 Dec;55(8):1364-75. doi: 10.1016/j.neuropharm.2008.08.032. Epub 2008 Sep 11. [PubMed:18824002]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:22